Overview

Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of Zevalin® in a Reduced Intensity Conditioning regimen followed by allogenic stem cell support in patients with aggressive lymphomas who are responsive to a salvage chemotherapy regimen.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Bordeaux

Collaborator:

Bayer

Treatments:

Antibodies, Monoclonal
Fludarabine
Fludarabine phosphate